Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.

Andrés F CardonaAlejandro Ruiz-PatiñoZyanya Lucia Zatarain-BarrónFernando HakimEnrique JiménezJuan Armando MejíaJuan Fernando RamónNicolás UsecheSonia BermúdezDiego PinedaHernando CifuentesLeonardo RojasLuisa RicaurteLuis Eduardo PinoCarmen BalañaArrieta Oscar

Published in: PloS one (2019)

Sunitinib and octreotide/everolimus have similar efficacy and safety in the systemic management of refractory meningioma. VEGFR2 and PDGFRβ expression are associated with better outcomes.

Keyphrases

renal cell carcinoma
metastatic renal cell carcinoma
poor prognosis
neuroendocrine tumors
adipose tissue
binding protein